Bomedemstat

DRUG15 trials

Sponsors

Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA), University of Washington, The University of Hong Kong, Terrence J Bradley, MD, Merck Sharp & Dohme LLC

Conditions

Acute Myeloid LeukemiaAcute Myeloid Leukemia, in RelapseEssential ThrombocythemiaExtensive Stage Lung Small Cell CarcinomaHealthyHepatic InsufficiencyLimited Stage Lung Small Cell CarcinomaMyelodysplastic Syndrome

Phase 1

A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001)

CompletedNCT02842827

Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)Acute Myeloid Leukemia, Myelodysplastic Syndrome

Start: 2016-10-06End: 2018-10-30Updated: 2023-07-11

Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)

CompletedNCT03136185

Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis (PET-MF), Post-polycythemia Vera Myelofibrosis (PPV-MF) +1

Start: 2017-07-18End: 2022-03-08Updated: 2024-01-10

Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer

TerminatedNCT05191797

University of WashingtonExtensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma

Start: 2022-04-11End: 2024-04-05Updated: 2024-09-26

Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia

RecruitingNCT05597306

Terrence J Bradley, MDAcute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse, Refractory Acute Myeloid Leukemia

Start: 2022-11-19End: 2026-11-19Target: 18Updated: 2026-01-08

Drug-Drug Interaction Study of Bomedemstat and Carbamazepine in Healthy Adult Participants (MK-3543-020)

CompletedNCT06596668

Merck Sharp & Dohme LLCHealthy

Start: 2024-10-02End: 2025-03-11Updated: 2025-03-18

A Study of Bomedemstat (MK-3543) in Participants With Mild or Moderate Hepatic Impairment (MK-3543-023)

CompletedNCT07049939

Merck Sharp & Dohme LLCHepatic Insufficiency

Start: 2025-08-20End: 2026-02-17Updated: 2026-02-25

Phase 2

Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)

CompletedNCT04254978

Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)Essential Thrombocythemia

Start: 2020-09-08End: 2023-03-23Updated: 2026-05-04

An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)

CompletedNCT05223920

Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)Primary Myelofibrosis, Thrombocythemia, Essential

Start: 2021-12-15End: 2024-08-22Updated: 2025-09-22

A Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Polycythemia Vera (IMG-7289-CTP-203/MK-3543-004)

CompletedNCT05558696

Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)Polycythemia Vera

Start: 2023-09-07End: 2025-07-10Updated: 2026-05-07

Bomedemstat (IMG-7289) Plus Ruxolitinib for Myelofibrosis

The University of Hong KongMyelofibrosis

Start: 2022-12-01End: 2025-12-31Target: 40Updated: 2023-05-23

Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis

Not yet recruitingNCT07424950

United Lincolnshire Hospitals NHS TrustMyelofibrosis

Start: 2026-11-01End: 2029-11-01Target: 40Updated: 2026-02-20

A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025)

Not yet recruitingNCT07722611

Merck Sharp & Dohme LLCPolycythemia Vera

Start: 2026-09-21End: 2032-11-30Target: 380Updated: 2026-07-23

Phase 3

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

Active, not recruitingNCT06079879

Merck Sharp & Dohme LLCEssential Thrombocythemia

Start: 2023-12-31End: 2028-08-18Target: 340Updated: 2026-08-13

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

RecruitingNCT06351631

Merck Sharp & Dohme LLCMyelofibrosis, Polycythemia Vera, Post-essential Thrombocythemia Myelofibrosis +3

Start: 2024-05-23End: 2034-12-04Target: 400Updated: 2026-04-02

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

Active, not recruitingNCT06456346

Merck Sharp & Dohme LLCEssential Thrombocythemia

Start: 2024-07-16End: 2028-03-24Target: 300Updated: 2026-08-27

Related Papers

The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study.

2026-04-29

Phase 2 study of the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat for essential thrombocythemia.

2026-02-27

Efficacy and safety of the LSD1 inhibitor bomedemstat in participants with polycythemia vera (PV) resistant or intolerant to cytoreductive therapy: The Phase 2 shorespan-004 study

Blood2025-11-03

Shorespan-017: Phase 3 extension study for safety of bomedemstat in participants with essential thrombocythemia who received bomedemstat from a prior clinical study

Blood2025-11-03

Shorespan-007: Phase 3 study of bomedemstat versus hydroxyurea in essential thrombocythemia naive to cytoreductive therapy.

Journal of Clinical Oncology2025-05-28

Bomedemstat (MK3543) in Combination with Ruxolitinib in Patients with Advanced Myelofibrosis

Blood2024-11-053 citations

A Phase 3, Randomized, Double-Blind, Active-Comparator-Controlled Study of Bomedemstat Versus Hydroxyurea in Patients with Essential Thrombocythemia Naïve to Cytoreductive Therapy

Blood2024-11-052 citations

Phase 3 study of the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in patients with essential thrombocythemia (ET).

Journal of Clinical Oncology2024-06-01

Phase 2 study of the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in patients with polycythemia vera (PV).

Journal of Clinical Oncology2024-06-01

Bomedemstat (IMG-7289), an LSD1 Inhibitor, Manages the Signs and Symptoms of Essential Thrombocythemia (ET) While Reducing the Burden of Cells Homozygous for Driver Mutations

Blood2023-11-029 citations

A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Advanced Myelofibrosis (MF): Updated Results and Genomic Analyses

Blood2022-11-1514 citations

A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Essential Thrombocythemia (ET)

Blood2022-11-1513 citations

P1051: A PHASE 2 STUDY OF IMG-7289 (BOMEDEMSTAT) IN PATIENTS WITH ADVANCED MYELOFIBROSIS

HemaSphere2022-06-0110 citations

P1033: A PHASE 2 STUDY OF THE LSD1 INHIBITOR IMG-7289 (BOMEDEMSTAT) FOR THE TREATMENT OF ESSENTIAL THROMBOCYTHEMIA (ET)

HemaSphere2022-06-0110 citations

A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Advanced Myelofibrosis

Blood2021-11-0521 citations

A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Essential Thrombocythemia (ET)

Blood2021-11-0513 citations

LSD1 Inhibition with IMG7289 (bomedemstat) Rebalances Megakaryopoiesis and Erythropoiesis in a Patient with MPN/MDS with Refractory Anemia with Ringed Sideroblast and Marked Thrombocytosis with JAK2 and SF3B1 Mutations

Blood2020-11-042 citations

Pharmacologic LSD1 Inhibition Preserves Human Granulocytic While Expanding Monocytic Progenitors

Blood2018-11-29